GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » Total Equity

DVHGF (Devonian Health Group) Total Equity : $10.54 Mil (As of Oct. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Devonian Health Group Total Equity?

Devonian Health Group's total equity for the quarter that ended in Oct. 2024 was $10.54 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Devonian Health Group Total Equity Historical Data

The historical data trend for Devonian Health Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devonian Health Group Total Equity Chart

Devonian Health Group Annual Data
Trend Jun15 Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.95 6.00 12.58 10.78 10.55

Devonian Health Group Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.23 9.80 9.76 10.55 10.54

Devonian Health Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Devonian Health Group's Total Equity for the fiscal year that ended in Jul. 2024 is calculated as

Total Equity=Total Assets(Q: Jul. 2024 )-Total Liabilities(Q: Jul. 2024 )
=22.41-11.865
=10.55

Devonian Health Group's Total Equity for the quarter that ended in Oct. 2024 is calculated as

Total Equity=Total Assets(Q: Oct. 2024 )-Total Liabilities(Q: Oct. 2024 )
=24.235-13.698
=10.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group Total Equity Related Terms

Thank you for viewing the detailed overview of Devonian Health Group's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Devonian Health Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » Total Equity
Comparable Companies
NEOE:BMND TSXV:TTI TSX:HBP TSXV:NRX XCNQ:DOSE TSX:SVA TSXV:SHRX TSX:BCT XCNQ:PHRM XCNQ:TELI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
GSD:Canada
Address
360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Website
https://www.groupedevonian.com
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.